Rheumatology Network Newsletter

ACR Annual Meeting Conference Report

Researchers Try to Reverse the Aging Process for Arthritic Joints

ACR Annual Meeting: Single intra-articular doses of UBX0101 of up to 4 mg were well-tolerated by patients with painful knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12. The treatment is in development, but if it pans out, it may reduce the effects aging on arthritic joints.

Emapalumab Shows Promise for Macrophage Activation Syndrome

In a small study, patients with macrophage activation syndrome (MAS) receiving emapalumab (Gamifant, Sobi) achieved complete response, according to data presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.

Is Tofacitinib as Monotherapy Enough for Psoriatic Arthritis?

ACR Annual Meeting: The use of methotrexate combined with, or without, the oral JAK inhibitor tofacitinib produced no clinically meaningful difference in 179 psoriatic arthritis patients from the OPAL Balance study, presented at ACR 2019 this week.

Cannabis Use Up Among Patients with Rheumatic Diseases

Cannabis use among patients with rheumatic diseases has increased since 2014, and those who tried cannabis tended to have worse pain, disease activity, and symptoms and were taking more analgesics, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 13.